ClinicalTrials.gg
RecruitingNCT06047262Dapan-DiaUpdated Feb 25, 2026

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

A Phase 2 interventional study of Dapansutrile and Placebo in Diabetes Mellitus, Type 2, sponsored by Marc Donath. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Marc Donath · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 414 studies in Diabetes Mellitus, Type 2 with a site in France — 36 open to participants now, 41 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · France.

Planned enrollment
173rd of 336
300 · median 312
Started
2024
with 14 others
Phase 2
31 of 414
2 open now
Primary completion
2028-07
later than 24 of 40 live
Registered
382nd of 414
by date

Among the 414 studies in Diabetes Mellitus, Type 2 with a site in France, this one is the 173rd largest by planned enrollment of the 336 interventional ones that give a count, is one of 15 that started in 2024, is one of 31 in phase 2, reaches primary completion later than 24 of the 40 other live ones, and was the 382nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

36 of the 414 studies in Diabetes Mellitus, Type 2 with a site in France are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 414 studies in Diabetes Mellitus, Type 2 with a site in France, or all of them as a file.
02

Study summary

The aim of the study is to determine whether NLRP3 inhibition with dapansutrile represents a new pharmacological option for diabetes management with potential as an anti-inflammatory agent to also address micro- and macro-vascular risk and complications from diabetes.

Read the detailed description

To date, no other oral NLRP3 inhibitor has sufficiently advanced in development to be tested in a chronic low-grade inflammatory disease such as type 2 diabetes mellitus over a period of 3 to 4 months as proposed in this trial. Based on the publicly available information, dapansutrile is the most advanced oral NLRP3 inhibitor in development. The rationale is built upon dapansutrile's clinical and extensive preclinical and safety findings, and from data in chronic animal toxicology studies to date, which together enable and support its investigation in select chronic low-grade inflammatory diseases. Therefore, the investigators have selected type 2 diabetes mellitus and its complications, including risk for cardiovascular disease, as a disease with clinical features of low-grade inflammation to further investigate the therapeutic potential of NLRP3 inhibition with dapansutrile.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2, Diabetes mellitus as defined by the criteria of the American Diabetes Association (ADA) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (see Appendix 1) and recognized by the World Health Organization (WHO, 2019), for at least 3 months prior to the Baseline Visit/Day 1
  • value of ≥ 7.7% to ≤ 11.0% at the Screening Visit.
  • High-sensitivity C-reactive protein (hsCRP) ≥ 1.5 mg/L at the Screening Visit.
  • (BMI) ≥25 to ≤ 40 kg/m2 at the Screening Visit
  • Acceptable overall medical condition to safely participate in the study and complete all study procedures (particularly with regard to cardiovascular, renal, and hepatic conditions), in the opinion of the Investigator

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 1 diabetes mellitus
  • value of ≤ 7.5% or ≥ 10.5% at the Baseline Visit/Day 1, as determined at point of care (local laboratory)
  • Use of thiazolidinediones (glitazones), pramlintide, or short-acting insulin/insulin analogues (as bolus or premixed insulin) within 12 weeks prior to the Screening Visit
  • Less than 80% compliance in taking medicinal product by pill count during the Run-In Period, as assessed at the Baseline Visit/Day 1
  • Significant weight loss (> 5 kg) in the 12 weeks prior to the Screening Visit
  • Systolic blood pressure (BP) ≥ 160 mmHg, diastolic BP ≥ 100 mmHg, or resting heart rate (HR) ≥ 100 beats/minute at the Screening Visit
  • Previous myocardial infarction, any cardiac surgery
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    1000 mg dapansutrile (2 × 500mg tablets) administered twice a day from day 1 through the week 26 visit, inclusive. All tablets will be self-administered by mouth with water, with or without food.

    Drug: Dapansutrile

  • Placebo comparator
    Control Group

    Matching placebo (2 tablets) administered twice a day from day 1 through the Week 26 visit, inclusive. All tablets will be self-administered by mouth with water, with or without food.

    Drug: Placebo

Interventions

  • Patients receive investigational product.

    Also known as: 3-methanesulfonyl-propionitrile, OLT1177

  • DrugPlacebo

    Patients receive placebo.

06

What researchers measure

Primary outcomes

  1. Change in HbA1c in blood of patients for dapansutrile compared to placebo

    Comparison of change in HbA1c for dapansutrile and placebo

    Time frame: two time assessment at baseline and week 26

Secondary outcomes

  1. Change in HbA1c in blood of patients for dapansutrile compared to placebo

    Comparison of change in HbA1c for dapansutrile and placebo

    Time frame: six time assessment at baseline and week 4, 8, 12, 16, 20

  2. Change in fasting plasma glucose for dapansutrile compared to placebo

    Comparison of change in fasting plasma glucose for dapansutrile and placebo

    Time frame: seven time assessement at baseline and week 4, 8, 12, 16, 20, 26

07

Study locations

5 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2028, 48 months after the start.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 48 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 21, 2023
StartActual
Jul 9, 2024
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06047262
Lead sponsor
Marc Donath
Collaborators
European Union, State Secretariat for Education Research and Innovation, Switzerland, Olatec Therapeutics, Inc., Departement Klinische Forschung Universität Basel, CTU Kantonsspital Baden
Responsible party
Marc Donath (Prof. Dr. med., Kantonsspital Baden) — Sponsor-investigator
First posted
Sep 21, 2023
Start date
Jul 9, 2024
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Feb 25, 2026

Study contacts

Marc Y. Donath, Prof.
Contact
marc.donath@umontreal.ca
+41 61 265 50 78
Markus Veit
Contact
markus.veit@ksb.ch
+41 56 486 25 14
Marc Y. Donath, Prof.
study chair · Kantonsspital Baden, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapansutrile

Start the discussion